Biotech company Vertex Pharmaceuticals (NASDAQ: VRTX) will be reporting results this Monday after the bell. Here’s what to look for.

Vertex Pharmaceuticals beat analysts’ revenue expectations last quarter, reporting revenues of $2.99 billion, up 8.2% year on year. It was a mixed quarter for the company, with a beat of analysts’ EPS estimates but full-year revenue guidance meeting analysts’ expectations.

Is Vertex Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Vertex Pharmaceuticals’s revenue to grow 7.6% year on year, slowing from the 12.1% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Vertex Pharmaceuticals has missed Wall Street’s revenue estimates multiple times over the last two years.

Looking at Vertex Pharmaceuticals’s peers in the therapeutics segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Biogen delivered year-on-year revenue growth of 3.4%, beating analysts’ expectations by 12.1%, and Moderna reported revenues up 2.1%, topping estimates by 35.8%. Biogen traded up 1.1% following the results.

Read our full analysis of Biogen’s results here and Moderna’s results here.

Investors in the therapeutics segment have had steady hands going into earnings, with share prices flat over the last month. Vertex Pharmaceuticals is down 10% during the same time and is heading into earnings with an average analyst price target of $557.13 (compared to the current share price of $476.99).

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.